BioSpace News Archive

FDA

FDA Approves GSK’s PARP Inhibitor Zejula for New Ovarian Cancer Indication

Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.

April 30, 2020
·
3 min read
·
Alex Keown
Drug Development

Gilead’s Remdesivir Speeds COVID-19 Recovery by 31% in NIAID Clinical Trial

“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”

April 30, 2020
·
3 min read
·
Mark Terry
Business

AstraZeneca Collaborates with Oxford’s Jenner Institute on COVID-19 Vaccine

AstraZeneca and the University of Oxford have partnered on the global development and distribution of Oxford’s COVID-19 vaccine it is developing.

April 30, 2020
·
3 min read
·
Mark Terry
Policy

Prosecutors Seek to Deny Martin Shkreli’s Furlough Appeal to Battle COVID-19

Disgraced pharmaceutical executive Martin Shkreli wants out of prison to help research a treatment for COVID-19, but federal prosecutors want him to remain behind bars for the duration of his sentence for fraud.

April 30, 2020
·
2 min read
·
Alex Keown
Drug Development

Biopharma Update on the Novel Coronavirus: April 30

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.

April 30, 2020
·
5 min read
·
BioSpace Editorial Staff
Research Roundup: Major Breakthrough in HIV Research and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

April 30, 2020
·
4 min read
·
Mark Terry
Business

Updated: A Ventilator Helmet Alternative for COVID-19 Patients

BioSpace spoke to Aurika Savickaite, RN, MSN, to learn more about the ventilator helmet initiative, NIV helmets, and how they can be used during this coronavirus pandemic.

April 30, 2020
·
7 min read
·
Chelsea Weidman Burke
Deals

resTORbio and Adicet Bio Merge to Advance T-Cell Therapies

The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.

April 30, 2020
·
2 min read
·
Mark Terry
Business

Faster Drug Development Processes Likely to Outlive COVID-19

The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.

April 30, 2020
·
5 min read
·
Gail Dutton
Business

During COVID-19, Biotech Professionals Feel Isolated and Less Productive

A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.

April 30, 2020
·
1 min read
·
Gail Dutton